.
<!--[if (gte mso 9)|(IE)]>
<![endif]--> <!--[if (gte mso 9)|(IE)]>
<![endif]-->
<!--[if (gte mso 9)|(IE)]>
<![endif]--> <!--[if (gte mso 9)|(IE)]>
<![endif]-->
<!--[if (gte mso 9)|(IE)]>
<![endif]--> <!--[if (gte mso 9)|(IE)]>
| <![endif]-->
<!--[if (gte mso 9)|(IE)]> |
<![endif]--> <!--[if (gte mso 9)|(IE)]>
<![endif]--> |
<!--[if (gte mso 9)|(IE)]> |
<![endif]--> <!--[if (gte mso 9)|(IE)]>
<![endif]-->
<!--[if (gte mso 9)|(IE)]>
<![endif]--> <!--[if (gte mso 9)|(IE)]>
<![endif]-->
|
FOR IMMEDIATE RELEASE – 07/22/2024 – Chula Vista, CA – Main Products, Inc. is voluntarily recalling all lots of “Umary Acido Hialuronico, Suplemento Alimenticio – 30 Capletas de 850mg” to the consumer level. FDA laboratory analysis confirmed that UMARY has been found to be tainted with the drug ingredients, diclofenac and omeprazole. Products containing diclofenac and omeprazole cannot be marketed as dietary supplements. Umary is an unapproved new drug for which safety and efficacy have not been established and, therefore, subject to recall.
Risk Statement: Diclofenac is a non-steroidal anti-inflammatory drug (commonly referred to as NSAIDs). There is a reasonable probability that consumption of high levels of undeclared diclofenac could result in serious adverse events that include cardiovascular, gastrointestinal, renal, and anaphylaxis in patients taking concomitant NSAIDs and/or anticoagulants, such as Warfarin, in those who have allergies to diclofenac, or those with underlying cardiovascular, gastrointestinal, renal, and hepatic illnesses.
|
<!--[if (gte mso 9)|(IE)]> |
<![endif]--> <!--[if (gte mso 9)|(IE)]>
<![endif]--> |
<!--[if (gte mso 9)|(IE)]> |
<![endif]-->
|